G&A at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s G&A?
- Mineralys Therapeutics, Inc. (MLYS) reported G&A of $20.98M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s G&A changed year-over-year?
- Mineralys Therapeutics, Inc.'s G&A increased by 219.4% year-over-year, from $6.57M to $20.98M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s G&A?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s G&A has grown at a 94.7% compound annual growth rate (CAGR), from $5.23M to $38.6M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.